Canakinumab (ACZ885, a fully human IgG1 anti-IL-1β mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS).docVIP

下载本文档

3
0
约4.07万字
约 10页
2017-05-16 发布于上海
举报

Canakinumab (ACZ885, a fully human IgG1 anti-IL-1β mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS).doc

Canakinumab (ACZ885, a fully human IgG1 anti-IL-1β mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS)

Kuemmerle-Deschneretal.ArthritisResearchTherapy2011,13:R34 /content/13/1/R34 RESEARCH ARTICLE OpenAccess Canakinumab(ACZ885,afullyhumanIgG1 anti-IL-1bmAb)inducessustainedremission inpediatricpatientswithcryopyrin-associated periodicsyndrome(CAPS) JasminBKuemmerle-Deschner1*,EduardoRamos2,NorbertBlank3,JoachimRoesler4,SandraDFelix5, ThomasJung5,KirstinStricker6,AbhijitChakraborty7,StaceyTannenbaum8,AndrewMWright9and ChristianeRordorf5 Abstract Introduction:Cryopyrin-associatedperiodicsyndrome(CAPS)representsaspectrumofthreeauto-inflammatory syndromes,familialcoldauto-inflammatorysyndrome(FCA

您可能关注的文档

文档评论（0）

1亿VIP精品文档

更多 >

Canakinumab (ACZ885, a fully human IgG1 anti-IL-1β mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS).docVIP